Home
TEVA
TEVA News

Latest Teva Pharmaceutical Industries Limited (TEVA) News on October 27, 2025

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Insider Monkey

5 days ago

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Teva (TEVA) Gains FDA Approval for UZEDY Injectable in Bipolar I Disorder Treatment – What's Changed

Simply Wall St.

6 days ago

Teva (TEVA) Gains FDA Approval for UZEDY Injectable in Bipolar I Disorder Treatment – What's Changed

All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to Buy

Zacks

6 days ago

All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to Buy

Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?

Zacks

6 days ago

Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?

Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?

Zacks

6 days ago

Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?

Johnson & Johnson Targets Accelerated Growth Across Segments in 2026

Zacks

6 days ago

Johnson & Johnson Targets Accelerated Growth Across Segments in 2026

Bank of America Securities Raises PT on Teva Pharmaceutical Industries (TEVA), Keeps a Buy

Insider Monkey

6 days ago

Bank of America Securities Raises PT on Teva Pharmaceutical Industries (TEVA), Keeps a Buy

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

Business Wire

6 days ago

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

Deckers Brands Announces Conference Call to Review Second Quarter Fiscal 2026 Earnings Results

Business Wire

14 days ago

Deckers Brands Announces Conference Call to Review Second Quarter Fiscal 2026 Earnings Results

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

Zacks

14 days ago

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid “Pivot to Growth” Strategy Execution

Insider Monkey

14 days ago

BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid “Pivot to Growth” Strategy Execution

Evaluating Teva (NYSE:TEVA) Valuation After FDA Expands UZEDY Approval to Bipolar I Disorder

Simply Wall St.

15 days ago

Evaluating Teva (NYSE:TEVA) Valuation After FDA Expands UZEDY Approval to Bipolar I Disorder

Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Business Wire

17 days ago

Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

MT Newswires

17 days ago

Teva, Medincell Announce US FDA's Expanded Indication for Uzedy to Treat Adults With Bipolar I Disorder

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

GlobeNewswire

17 days ago

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know

Zacks

17 days ago

Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know

Teva (TEVA) Is Up 9.2% After New Schizophrenia Drug Data and Innovation Shift - What’s Changed

Simply Wall St.

24 days ago

Teva (TEVA) Is Up 9.2% After New Schizophrenia Drug Data and Innovation Shift - What’s Changed

Can Galafold Drive Amicus' Growth Through the Rest of 2025?

Zacks

25 days ago

Can Galafold Drive Amicus' Growth Through the Rest of 2025?

UBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00

Insider Monkey

a month ago

UBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00

Truist Securities Reaffirms Its Buy Rating for Teva Pharmaceutical Industries Limited (TEVA)

Insider Monkey

a month ago

Truist Securities Reaffirms Its Buy Rating for Teva Pharmaceutical Industries Limited (TEVA)

Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?

Zacks

a month ago

Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?

Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®

Business Wire

a month ago

Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®

Morningstar Research

a month ago

Analyst Report: Teva Pharmaceutical Industries Limited

J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?

Zacks

a month ago

J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?

Business Wire

a month ago

Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed

Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®

Business Wire

a month ago

Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®

Teva Pharmaceutical Industries (NYSE:TEVA): Evaluating Valuation Potential After Recent Share Movement

Simply Wall St.

a month ago

Teva Pharmaceutical Industries (NYSE:TEVA): Evaluating Valuation Potential After Recent Share Movement

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

GlobeNewswire

a month ago

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

GlobeNewswire

a month ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

Zacks

a month ago

J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth

Zacks

a month ago

Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Business Wire

a month ago

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

GlobeNewswire

a month ago

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Teva Pharmaceutical Industries (TEVA) Attains FDA’s Fast Track Designation for Emrusolmin

Insider Monkey

a month ago

Teva Pharmaceutical Industries (TEVA) Attains FDA’s Fast Track Designation for Emrusolmin

How Is Deckers Outdoor Corporation's Stock Performance Compared to Other Consumer Discretionary Stocks?

Barchart

a month ago

How Is Deckers Outdoor Corporation's Stock Performance Compared to Other Consumer Discretionary Stocks?

Teva Pharmaceutical Industries Limited (TEVA)’s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy

Insider Monkey

a month ago

Teva Pharmaceutical Industries Limited (TEVA)’s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy

J.P. Morgan Maintains a Buy on Teva Pharmaceutical (TEVA) With a $23 PT

Insider Monkey

2 months ago

J.P. Morgan Maintains a Buy on Teva Pharmaceutical (TEVA) With a $23 PT

Here’s Why Sound Shore Fund Added Teva Pharmaceutical Industries Limited (TEVA) in Q2

Insider Monkey

2 months ago

Here’s Why Sound Shore Fund Added Teva Pharmaceutical Industries Limited (TEVA) in Q2

Teva (NYSE:TEVA) Valuation in Focus After FDA Approval and U.S. Launch of Generic Saxenda

Simply Wall St.

2 months ago

Teva (NYSE:TEVA) Valuation in Focus After FDA Approval and U.S. Launch of Generic Saxenda

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Zacks

2 months ago

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Anti-Parkinson's Drugs Global Market Research Report 2025-2030 | $9.2 Bn Opportunities Driven by Increased Awareness in Emerging Countries and a Robust Pipeline of Innovations

GlobeNewswire

2 months ago

Anti-Parkinson's Drugs Global Market Research Report 2025-2030 | $9.2 Bn Opportunities Driven by Increased Awareness in Emerging Countries and a Robust Pipeline of Innovations

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

GlobeNewswire

2 months ago

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda

Insider Monkey

2 months ago

Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda

Did FDA Approval of Generic Saxenda Just Shift Teva's (TEVA) Investment Narrative?

Simply Wall St.

2 months ago

Did FDA Approval of Generic Saxenda Just Shift Teva's (TEVA) Investment Narrative?

Teva brings first generic GLP-1 to US market with Saxenda copycat approval

Pharmaceutical Technology

2 months ago

Teva brings first generic GLP-1 to US market with Saxenda copycat approval

Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY

Insider Monkey

2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

Investor's Business Daily

2 months ago

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

Deckers Outdoor (DECK) Sees 12% Rise in Share Price Over Past Week

Simply Wall St.

2 months ago

Deckers Outdoor (DECK) Sees 12% Rise in Share Price Over Past Week

MT Newswires

2 months ago

Teva Pharmaceuticals Launches Generic Weight Loss Injection Saxenda; Shares Up Pre-Bell

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

GlobeNewswire

2 months ago

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

MT Newswires

2 months ago

Catalyst Pharmaceuticals Says Settlement Reached With Lupin Pharmaceuticals in Firdapse Patent Litigation

Deckers Outdoor (DECK): Assessing Valuation After New Teva Launches and Continued Earnings Momentum

Simply Wall St.

2 months ago

Deckers Outdoor (DECK): Assessing Valuation After New Teva Launches and Continued Earnings Momentum

Simply Wall St.

2 months ago

Will Teva’s Designer Collaboration and New Collection Signal a Brand Evolution for Deckers (DECK)?

CalPrivate Bank Appoints Angel Martinez to the CalPrivate Bank Board

GlobeNewswire

2 months ago

CalPrivate Bank Appoints Angel Martinez to the CalPrivate Bank Board

Latest Fed cut signals, pharma relief rally, Apple TV+ price hike

Yahoo Finance Video

2 months ago

Latest Fed cut signals, pharma relief rally, Apple TV+ price hike

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

GlobeNewswire

2 months ago

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

US-EU trade deal impacts on pharma industry more 'manageable' than expected

Yahoo Finance

2 months ago

US-EU trade deal impacts on pharma industry more 'manageable' than expected

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

Zacks

2 months ago

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

Teva Debuts Autumn Winter 2025 Collection Inspired By "For Playground Earth"

Business Wire

2 months ago

Teva Debuts Autumn Winter 2025 Collection Inspired By "For Playground Earth"

Teva Releases Q2 2025 Aide Memoire

GlobeNewswire

4 months ago

Teva Releases Q2 2025 Aide Memoire

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Insider Monkey

4 months ago

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

GlobeNewswire

4 months ago

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?

Motley Fool

4 months ago

Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?

Teva reports final analysis of migraine prevention trial of Ajovy

Clinical Trials Arena

4 months ago

Teva reports final analysis of migraine prevention trial of Ajovy

Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth

Insider Monkey

4 months ago

Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth

J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?

Zacks

4 months ago

J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

GlobeNewswire

4 months ago

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

Zacks

4 months ago

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing

The Wall Street Journal

4 months ago

Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing

Teva, Fosun Pharma partner to develop TEV-56278

TipRanks

4 months ago

Teva, Fosun Pharma partner to develop TEV-56278

Teva to collaborate with Fosun Pharma for TEV-56278

Pharmaceutical Technology

4 months ago

Teva to collaborate with Fosun Pharma for TEV-56278

MT Newswires

4 months ago

Teva Pharmaceutical Industries Insider Sold Shares Worth $952,464, According to a Recent SEC Filing

MT Newswires

4 months ago

Teva Pharmaceutical, Shanghai Fosun Partner to Develop Cancer Treatment Drug

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

GlobeNewswire

4 months ago

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

Motley Fool

4 months ago

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris

Zacks

5 months ago

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

Zacks

5 months ago

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

CrowdStrike and McDonald’s downgraded: Wall Street’s top analyst calls

TipRanks

5 months ago

CrowdStrike and McDonald’s downgraded: Wall Street’s top analyst calls

Investing.com

5 months ago

Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

GlobeNewswire

5 months ago

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

MT Newswires

5 months ago

Teva Pharmaceutical Industries Raises Pool Tender Offer, Reports Early Tender Results

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

GlobeNewswire

5 months ago

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Morningstar Research

5 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

GlobeNewswire

5 months ago

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

GlobeNewswire

5 months ago

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

Morningstar Research

5 months ago

Analyst Report: Teva Pharmaceutical Industries Limited

Morningstar Research

5 months ago

Analyst Report: Teva Pharmaceutical Industries Limited

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

Insider Monkey

5 months ago

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

GlobeNewswire

5 months ago

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

Zacks

5 months ago

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

MT Newswires

5 months ago

Truist Securities Initiates Teva Pharmaceutical Industries at Buy With $25 Price Target

Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead

Motley Fool

5 months ago

Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead

Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408

Insider Monkey

5 months ago

Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408

MT Newswires

5 months ago

Teva Pharmaceutical Receives FDA Fast Track Designation for Drug to Treat Celiac Disease

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

GlobeNewswire

5 months ago

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

GlobeNewswire

5 months ago

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Why Is Teva Stock Trading Higher On Tuesday?

Benzinga

5 months ago

Why Is Teva Stock Trading Higher On Tuesday?

TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?

Zacks

5 months ago

TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?

MT Newswires

5 months ago

Teva Pharmaceutical Industries Begins Preclinical Testing of Inflammation Drug BD9

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

GlobeNewswire

5 months ago

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Share on Social Networks: